Contriven solution for injection, 10,000 IU/mL, 1 mL each, No. 10 in ampoules.
Ingredients
Active ingredient: aprotinin;
1 mL of solution contains: 10,000 KIO of aprotinin;
excipients: sodium chloride, water for injection.
Dosage Form
Solution for injection.
Main physical and chemical properties: a clear, colorless or slightly yellowish liquid.
Pharmacotherapeutic group
Protease inhibitors. Aprotinin. ATC code B02A B01.
Pharmacological properties
Pharmacodynamics.
Aprotinin is a broad-spectrum protease inhibitor molecule with antifibrinolytic activity. By forming a reversible stoichiometric “enzyme–inhibitor” complex, aprotinin inhibits trypsin, plasmin, and kallikrein in human blood plasma and tissues, leading to the inhibition of fibrinolysis.
In addition, it inhibits the contact phase of blood coagulation, which is a factor in triggering the coagulation process and stimulating fibrinolysis.
Aprotinin is used during surgeries involving cardiopulmonary bypass, as it reduces inflammatory responses, leading to a decreased need for allogeneic blood transfusions and reduced blood loss, as well as a reduced need for repeat mediastinal exploration due to bleeding.
In patients who underwent aortocoronary bypass surgery, the incidence of a 0.5 mg/dL increase in serum creatinine levels from baseline was significantly higher in patients who received the full dose of aprotinin compared with the placebo group. In most cases, postoperative renal dysfunction was reversible and not severe; the incidence of an increase in serum creatinine levels of 2 mg/dL or more relative to baseline was the same in the group that received the full dose of aprotinin and in the placebo group.
Pharmacokinetics.
After intravenous administration, aprotinin is rapidly distributed throughout the extracellular space, accompanied by a rapid decrease in aprotinin concentration in blood plasma; the half-life ranges from 0.3 to 0.7 hours. Later, specifically 5 hours after administration, the terminal elimination phase begins, during which the half-life ranges from 5 to 10 hours.
The placenta is likely not completely impermeable to aprotinin; however, penetration appears to occur extremely slowly.
During surgery, the mean steady-state plasma concentrations of the drug in patients who received aprotinin during cardiac surgery ranged from 175 to 281 KIOD/mL when the following regimen was used:
2,000,000 KIOD as an initial intravenous dose; 2,000,000 KIOD in the initial pump fill solution and 500,000 KIOD per hour as a continuous intravenous infusion throughout the surgery. The mean steady-state plasma concentration of the drug during surgery after administration of half this dose ranged from 110 to 164 KIOD/mL.
Data from pharmacokinetic studies of aprotinin in healthy volunteers, in cardiac patients undergoing surgery under cardiopulmonary bypass, and in women undergoing hysterectomy indicate that the pharmacokinetic parameters are linear over a dose range of 50,000 KIOD to 2,000,000 KIOD.
Plasma protein binding was studied ex vivo. Approximately 20% of the antifibrinolytic activity was attributable to the unbound form in the protein-free fraction, while 80% of the drug was bound to serum proteins.
At steady state, the volume of distribution was approximately 20 liters, and total clearance from the human body was approximately 40 mL per minute.
Aprotinin accumulated in the kidneys and, to a lesser extent, in cartilage tissue.
Accumulation of the drug in the kidneys results from the binding of aprotinin to the brush border of the epithelial cells of the proximal tubules, as well as its accumulation in the phagolysosomes of these cells. Accumulation in cartilage is due to the affinity of native aprotinin for acidic proteoglycans.
In other organs, the drug concentration was generally no different from that in blood serum. The lowest concentration of the drug was observed in the brain; aprotinin was practically absent in the cerebrospinal fluid.
Only a small amount of aprotinin crosses the placental barrier. The placenta cannot be considered completely impermeable to aprotinin; however, the rate of penetration is extremely low.
The transfer of aprotinin into breast milk has not been studied.
Metabolism, Elimination, and Excretion.
In the kidneys, the aprotinin molecule is broken down by lysosomal enzymes into shorter peptides or amino acids. In humans, less than 5% of the administered dose of aprotinin is excreted in the urine. Following intravenous administration of 131I-labeled aprotinin to healthy volunteers, 25% to 40% of the labeled substance is excreted in the urine as metabolites within 48 hours. These metabolites showed no inhibitory activity against enzymes.
There are currently no data on the use of the drug in patients with end-stage renal impairment; however, no clinically significant pharmacokinetic changes or apparent adverse effects were observed in patients with impaired renal function. Therefore, no special dose adjustment is required in such cases.
Indications
Aprotinin is indicated for prophylaxis to reduce postoperative blood loss and the need for blood transfusion in adult patients at high risk of major blood loss during isolated cardiopulmonary bypass (i.e., coronary artery bypass grafting not combined with other cardiovascular procedures).
Contraindications
Hypersensitivity to the active ingredient (bovine protein) or to any of the excipients; disseminated intravascular coagulation (DIC). In patients with specific IgG antibodies to aprotinin, there is an increased risk of anaphylaxis during treatment with aprotinin. Therefore, aprotinin therapy is contraindicated in such patients.
If testing for specific IgG antibodies to aprotinin is not possible before starting treatment, but it is suspected that the patient has received aprotinin therapy within the previous 12 months, administration of aprotinin is contraindicated.
Drug Interactions and Other Interactions
This drug should not be mixed with other medications, including beta-lactam antibiotics (incompatible). Administration of this drug is prohibited in combination with solutions containing dextran, corticosteroids, or parenteral nutrition solutions containing amino acids and lipids.
Depending on the dose, Contriven reduces the activity of streptokinase and urokinase. It may inhibit the activity of nonspecific serum cholinesterase. In patients with reduced nonspecific cholinesterase activity, the concomitant use of aprotinin and succinylcholine may cause apnea due to muscle relaxation.
Aprotinin inhibits the action of thrombolytic agents, including streptokinase, urokinase, and alteplase (r-tPA = recombinant tissue plasminogen activator), and the inhibitory effect is dose-dependent. If necessary, it can be diluted in a 0.9% sodium chloride solution or in at least 500 mL of a 5% glucose solution. The drug, when dissolved in glucose, should be used within 4 hours.
Administration of the drug into heparinized blood prolongs whole blood clotting time.
The use of aprotinin may lead to impaired renal function, especially in patients with pre-existing renal impairment. The use of aminoglycosides also increases the risk of developing renal impairment.
Special Considerations for Use
Aprotinin should not be used during aortocoronary bypass surgery (ACBS) in combination with other cardiovascular surgeries, as the benefit-risk ratio of aprotinin use during other cardiovascular surgeries has not been established.
Treatment with aprotinin may be associated with impaired renal function, particularly in patients with pre-existing kidney damage. In patients who underwent coronary artery bypass grafting, it was shown that the group receiving aprotinin had a 0.5 mg/dL increase in serum creatinine levels compared to normal values (see the “Pharmacodynamics” section). Accordingly, before prescribing aprotinin to patients with impaired renal function or those at risk of renal impairment (e.g., during concomitant treatment with aminoglycosides), a careful assessment of the benefit-risk ratio is necessary.
Aprotinin should be used with caution in patients with atopic dermatitis, as pseudoallergic reactions may occur.
When using aprotinin, a careful assessment of the benefit-risk ratio is necessary, especially in patients who have previously used aprotinin (including fibrin sealants containing aprotinin), as they may develop an allergic reaction (see the “Adverse Reactions” section). Although in most cases anaphylaxis develops after administration of an approved dose within 12 months, there have been isolated reports of anaphylactic reactions occurring upon re-administration after 12 months. When administering aprotinin therapy, emergency treatment for allergic and anaphylactic reactions must be readily available.
All patients receiving aprotinin therapy must first receive a test dose to assess susceptibility to allergic reactions (see the “Dosage and Administration” section). The test dose should be administered to the patient in the operating room.
H1 and H2 antagonists may be administered 15 minutes before the aprotinin test.
The test dose of aprotinin for all patients should be 1 milliliter (10,000 KIOD), after which the patient must be monitored for at least 10 minutes before administering the loading dose (see the “Dosage and Administration” section).
However, even in the absence of complications following administration of the initial dose
1 mL, the therapeutic dose of aprotinin may cause an anaphylactic reaction. If an anaphylactic reaction develops, the aprotinin infusion should be discontinued and the necessary emergency measures taken.
Due to the potential for hypersensitivity reactions (see the “Adverse Reactions” section), the benefit-risk ratio must be carefully assessed for each patient who has previously received aprotinin therapy (see the “Adverse Reactions” section).
If it is known that a patient has already received or may have received repeat treatment with aprotinin, it is recommended to take precautionary measures. As stated in the “Dosage and Administration” section, all patients should receive a test dose of 1 milliliter (10,000 KIOD) of aprotinin at least 10 minutes before administration of the initial dose. In addition, an H1 antagonist (e.g., clemastine) and an H2 antagonist (e.g., cimetidine) may be administered 15 minutes before the test dose. If necessary, standard emergency measures should be used to treat an allergic (anaphylactic) reaction.
However, it should not be forgotten that a therapeutic dose may cause an allergic reaction, even if the patient tolerated the initial 1-milliliter test dose well without experiencing any adverse symptoms. If this occurs, the aprotinin infusion should be discontinued immediately, and standard emergency measures for treating an anaphylactic reaction should be initiated.
Patients who received aprotinin showed an increased incidence of renal dysfunction and mortality, compared with an age-matched control group that had a similar medical history and in which thoracic aortic surgery was also performed under cardiopulmonary bypass with cardiac arrest in the context of deep hypothermia. In such cases, aprotinin should be administered with extreme caution. Appropriate anticoagulant therapy with heparin is required.
Monitoring of laboratory parameters of anticoagulation during aortocoronary bypass surgery.
The use of aprotinin does not reduce the amount of heparin required; therefore, it is very important that adequate anticoagulant activity resulting from heparin administration be maintained during aprotinin therapy. In patients receiving aprotinin therapy, an increase in partial thromboplastin time (PTT) and celite-activated clotting time (celite-ACT) is expected during surgery and for several hours afterward.
Therefore, the partial thromboplastin time (PTT) should not be used to monitor the maintenance of adequate anticoagulant activity with heparin. In patients undergoing aortocoronary bypass surgery with the use of aprotinin, one of the following three methods is recommended to maintain adequate anticoagulant activity: Activated clotting time (ACT), administration of fixed doses of heparin, or titration of heparin doses (see below).
When using activated clotting time (ACT) to maintain adequate anticoagulant activity, the minimum recommended duration for the Celite-750 s aPTT test or the kaolin-480 s aPTT test is in the presence of aprotinin, regardless of the effects of hemodilution and hypothermia.
Additional notes on the use of the drug during cardiopulmonary bypass.
To maintain adequate anticoagulant activity during cardiopulmonary bypass with concomitant use of aprotinin, it is recommended to use any of the following methods:
1. Activated clotting time (ACT): ACT cannot be considered a standard coagulation test; interpretation of this test’s results depends on the presence of aprotinin. In addition, test results are influenced by dilution-related variations and the temperature used during cardiopulmonary bypass. It has been shown that the effect of aprotinin is less pronounced with kaolin-based ACT compared to ACT using diatomaceous earth (cellite). Despite the variety of protocols, it is recommended to perform a 750-second APTT test using diatomaceous earth or a 480-second APTT test using kaolin in the presence of aprotinin, regardless of the degree of hemodilution and hypothermia. For guidance on interpreting test results in the presence of aprotinin, consult the manufacturer of the APTT test reagents.
2. Administration of continuous heparin doses: The standard loading dose of heparin administered prior to cardiac catheterization, as well as the amount of heparin added to the initial priming solution of the cardiopulmonary bypass machine, should be at least 350 IU/kg. The additional dose of heparin is determined based on the patient’s body weight and the duration of the procedure under cardiopulmonary bypass.
3. Heparin/protamine titration: The results of this method are not affected by the presence of aprotinin; therefore, it is acceptable for measuring heparin levels. The relationship between the heparin dose and the response to it should be assessed by protamine titration prior to the administration of aprotinin (to determine the loading dose of heparin).
Additional heparin may be administered based on the heparin concentration measured by protamine titration. The heparin concentration during cardiopulmonary bypass should not fall below 2.7 U/mL (2 mg/kg) or below the dose determined during the heparin dose-response test performed prior to the administration of aprotinin.
After the completion of cardiopulmonary bypass, if the patient has received aprotinin injections, heparin should be neutralized by administering protamine. The amount of protamine should be calculated based on a fixed ratio, which is determined by the amount of heparin administered or calculated using the protamine titration method.
Important: The use of aprotinin does not mean that the need for heparin is reduced; aprotinin must not be used as a heparin-sparing agent.
This medicinal product contains less than 1 mmol (8.5 mg)/1 mL of sodium and (42.5 mg)/5 mL of sodium, i.e., it is practically sodium-free.
Use During Pregnancy or Breastfeeding
No adequate and well-controlled studies have been conducted in pregnant women. Results from animal studies do not indicate any teratogenic or embryotoxic effects of aprotinin. Aprotinin is contraindicated during the first trimester of pregnancy and should not be used during the second and third trimesters, except in cases where the potential benefit outweighs the expected risk. In the event of serious adverse reactions (such as anaphylactic reactions, cardiac arrest, etc.) and during their treatment, the potential risk to the fetus should be taken into account when assessing the risk-benefit ratio (see the “Special Considerations for Use” section).
It is unknown whether aprotinin is excreted into breast milk. There is no information available on the use of Contriven during breastfeeding. However, since aprotinin is not bioavailable when taken orally, any amount of the drug that enters breast milk will not affect the infant.
Effect on the ability to drive or operate machinery
This medication may only be administered in a hospital setting.
Dosage and Administration
Before starting treatment, all patients must undergo a test for specific IgG antibodies to aprotinin (see the “Contraindications” section). The following dosages are recommended for adult patients:
Test dose.
Due to the risk of an allergic (anaphylactic) reaction, all patients should receive an intravenous injection of 10,000 KIOD (kallikrein-inhibiting units) of aprotinin (1 mL) intravenously at least 10 minutes before administration of the initial dose. If the initial dose of 1 mL does not cause an allergic reaction, the therapeutic dose may be administered.
H1 and H2 antagonists may be administered 15 minutes before the aprotinin test. Equipment for standard emergency treatment of anaphylactic and allergic reactions must be available.
During open-heart surgery (with a heart-lung machine) to reduce blood loss and the need for blood transfusion:
After induction of anesthesia (but before sternotomy), it is recommended to administer a loading dose of 1,000,000 to 2,000,000 KIOD by slow intravenous injection or infusion over 20–30 minutes. The next 1,000,000–2,000,000 KIOD should be administered after the heart-lung machine is turned on. To avoid physical incompatibility between aprotinin and heparin, which is added to the pump’s priming solution, each drug should be added to the pump’s priming solution during recirculation to ensure sufficient dilution of both drugs before they mix with each other. Following the initial high-dose bolus infusion, 250,000 to 500,000 KIOD per hour should be administered via continuous infusion until the end of the operation.
In total, the total amount of aprotinin administered during the treatment cycle should not exceed 6,000,000 KIOD.
Intravenous aprotinin should be administered via a central venous catheter, which should not be used to administer any other medication.
The drug may be administered only to patients who are lying down; administration should be performed slowly (maximum rate: 5 to 10 mL per minute) by intravenous injection or short-term infusion.
Patients with renal impairment: Based on clinical experience to date, no dose adjustment is necessary.
Use in elderly patients: Based on current clinical experience, no adjustment of the dosing regimen is necessary for elderly patients.
Do not use the product if the contents of the ampoule appear cloudy. Once the ampoule is opened, the solution must be used immediately.
Children
The efficacy and safety of this medication in children have not been established.
Overdose
Symptoms of overdose or toxicity have not been described. There is no specific antidote. Symptomatic treatment is recommended.
Side Effects
In patients receiving aprotinin for the first time, the development of allergic or anaphylactic reactions is unlikely. In the event of repeated administration, the incidence of allergic (anaphylactic) reactions may reach 5%. A retrospective analysis of allergic (anaphylactic) reactions showed that their incidence increases if repeat administration occurs within 6 months of the initial treatment (the incidence is 5% with re-administration within 6 months and 0.9% with re-administration after 6 months). In addition, a retrospective analysis showed that the incidence of severe anaphylactic reactions is further increased in patients who received aprotinin more than twice within 6 months. Even if a patient has tolerated repeated treatment with aprotinin well, a subsequent administration may cause a severe allergic reaction or, in extremely rare cases, fatal anaphylactic shock.
Symptoms of allergic or anaphylactic reactions:
Cardiovascular system: hypotension, rapid heart rate, irregular heartbeat, blue lips;
Gastrointestinal system: nausea;
Respiratory system: bronchial asthma (bronchospasm);
skin and skin appendages: itching, hives, skin rashes, pallor;
psychiatric disorders: psychosis, hallucinations, confusion;
Other: shortness of breath, profuse sweating.
If an allergic reaction develops during an injection or infusion, administration of the drug must be stopped immediately. Standard emergency measures should be used, including administration of epinephrine, corticosteroids, and infusion therapy.
Cardiovascular system.
In patients who underwent aortocoronary bypass surgery, no significant differences in the incidence of myocardial infarction were observed compared with the placebo group. In some studies, there was a trend toward an increased incidence of myocardial infarction during aprotinin administration, whereas in other studies, conversely, a decrease in the number of myocardial infarctions was observed.
Since the objective of the aforementioned studies was not to identify differences in the incidence of myocardial infarction, an increased likelihood of clinically significant adverse effects cannot be statistically ruled out.
In a study in which patients underwent their first aortocoronary bypass surgery, the risk of graft occlusion was higher in patients who received aprotinin compared with the placebo group. As shown by a reanalysis, inadequate heparinization was performed at one of these centers, while an unapproved method of graft preservation was used at another. In addition to the remarks regarding heparinization (see the “Special Considerations for Use” section), it should be emphasized that the practice of drawing blood samples for testing from the main intravenous line used for the administration of aprotinin is absolutely unacceptable. Taking these factors into account, no differences were observed between the individual treatment groups in the incidence of myocardial infarction or in mortality rates.
Within each group, adverse reactions are listed in order of decreasing severity.
| Clinical Description | Common: > 1% to < 10% | Uncommon: > 0.1% to
< 1% |
Rare: > 0.01% to < 0.1% | Rare < 0.01% |
| Systemic disorders and reactions at the injection site | ||||
| Reactions at the injection site. | Reactions occurring at the injection or infusion site.
(Thrombo)phlebitis at the infusion site. |
|||
| Cardiac | ||||
| Myocardial disorders. | Myocardial infarction. | Myocardial ischemia
Coronary artery occlusion/thrombosis. |
||
| Pericardial effusion. | Pericardial effusion. | |||
| Vascular | ||||
| Embolisms and thromboses. | Thrombosis. | Arterial thrombosis (and its forms characteristic of vital organs, such as the kidneys, lungs, and brain). | Pulmonary embolism. | |
| Blood and lymphatic system | ||||
| Coagulation disorders. | Disseminated intravascular coagulation (DIC).
Coagulopathy. |
|||
| Immune system disorders | ||||
| Acute hypersensitivity reactions. | Allergic reactions.
Anaphylactic/anaphylactoid reactions. |
Anaphylactic shock (potentially life-threatening). | ||
| Renal and urinary system | ||||
| Renal dysfunction. | Impaired renal function.
Acute renal failure. Renal tubular necrosis. Oliguria. |
|||
Additional adverse reactions identified during the postmarketing period with the use of aprotinin: skin flushing, sensation of heat, tachycardia, weakness, chills, hyperthermia, dizziness, vomiting, itching, angioedema.
Shelf life
2 years.
Storage conditions
In the original packaging to protect from light at a temperature not exceeding 25°C. Keep out of the reach of children.
Incompatibility
Aprotinin should be considered practically incompatible with other medications. This medication must not be administered in mixed infusions. Due to chemical incompatibility, it must not be used concurrently with corticosteroids or with nutrient solutions containing amino acids and fats.
Packaging
1 mL in ampoules No. 10 (5×2) in blister packs in a cardboard box; 5 mL in ampoules No. 5 (5×1) in blister packs in a cardboard box.
Manufacturer
LLC “FZ ‘BIOFARMA’,” Ukraine.
Manufacturer’s location and business address.
Ukraine, 09100, Kyiv Oblast, Bila Tserkva, 37 Kyivska St.
Similar products
Products from the same category









